Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial.

Robert L Coleman Domenica Lorusso Ana OakninSabrina Chiara CecereHannelore G DenysNicoletta ColomboToon Van GorpJason A KonnerMargarita Romeo MarinPhilipp HarterConleth MurphyYuemei WangBrooke EstevesMichael MethodUrsula A Matulonis

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2024)

These results support the clinically meaningful efficacy of mirvetuximab soravtansine-gynx in FRα-expressing platinum-resistant ovarian cancer, irrespective of prior treatment or sequence.

Keyphrases

phase iii
clinical trial
study protocol
phase ii
amino acid
randomized controlled trial
stem cells
open label
binding protein